|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108.85 USD | +1.61% |
|
+3.65% | +8.21% |
| 04-17 | Nuvalent, Inc - Nuvalent anticipates U.S. commercial launch of Zidesamtinib in 2026 | RE |
| 04-17 | Nuvalent Inc Presents New Clinical and Preclinical Data for Zidesamtinib | CI |
| Capitalization | 8.56B 7.3B 6.7B 6.33B 11.69B 803B 11.95B 78.65B 30.98B 384B 32.1B 31.44B 1,364B | P/E ratio 2026 * |
-19.1x | P/E ratio 2027 * | -24.8x |
|---|---|---|---|---|---|
| Enterprise value | 7.69B 6.57B 6.02B 5.7B 10.51B 722B 10.75B 70.72B 27.86B 346B 28.86B 28.27B 1,227B | EV / Sales 2026 * |
557x | EV / Sales 2027 * | 41.3x |
| Free-Float |
85.54% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nuvalent, Inc.
| 1 day | +1.61% | ||
| 1 week | +3.65% | ||
| Current month | +6.25% | ||
| 1 month | +14.86% | ||
| 3 months | -0.17% | ||
| 6 months | +12.01% | ||
| Current year | +8.21% |
| 1 week | 101.79 |  | 109.53 |
| 1 month | 93.91 | | 109.53 |
| Current year | 93.91 | | 113.02 |
| 1 year | 63.56 | | 113.02 |
| 3 years | 33.03 | | 113.51 |
| 5 years | 7.09 | | 113.51 |
| 10 years | 7.09 | | 113.51 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Porter
CEO | Chief Executive Officer | 50 | 31/12/2016 |
Alexandra Balcom
DFI | Director of Finance/CFO | 42 | 31/12/2020 |
Henry Pelish
CTO | Chief Tech/Sci/R&D Officer | - | 10/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
James Porter
BRD | Director/Board Member | 50 | 31/01/2020 |
Cameron Wheeler
CHM | Chairman | 47 | 31/01/2017 |
Joseph Pearlberg
BRD | Director/Board Member | 62 | 31/12/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.61% | +3.65% | +55.61% | +215.14% | 8.42B | |
| -1.17% | -3.77% | +29.42% | +92.18% | 50.17B | |
| +0.71% | -6.85% | +84.17% | +29.89% | 43.62B | |
| +2.48% | -5.81% | +107.85% | +692.97% | 30.43B | |
| -2.69% | +10.35% | +6.67% | -8.18% | 28.22B | |
| -6.82% | +17.89% | -2.54% | +1,465.61% | 20.45B | |
| -0.79% | -5.91% | +70.83% | -30.45% | 18.65B | |
| +1.77% | +8.27% | +79.99% | +251.29% | 17.26B | |
| +2.51% | -3.66% | +37.48% | -36.34% | 16.71B | |
| -1.46% | +1.65% | +72.81% | - | 14.9B | |
| Average | -0.39% | +2.35% | +54.23% | +296.90% | 24.89B | |
| Weighted average by Cap. | -0.47% | +1.02% | +54.04% | +263.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.81M 11.79M 10.81M 10.23M 18.87M 1.3B 19.29M 127M 50.02M 621M 51.81M 50.75M 2.2B | 183M 156M 143M 135M 250M 17.17B 256M 1.68B 663M 8.22B 686M 672M 29.17B |
| Net income | -444M -379M -347M -329M -606M -41.63B -620M -4.08B -1.61B -19.94B -1.66B -1.63B -70.76B | -350M -299M -274M -259M -478M -32.83B -489M -3.22B -1.27B -15.73B -1.31B -1.29B -55.8B |
| Net Debt | -863M -736M -675M -639M -1.18B -80.9B -1.2B -7.93B -3.12B -38.75B -3.24B -3.17B -137B | -1B -854M -783M -741M -1.37B -93.85B -1.4B -9.2B -3.62B -44.95B -3.75B -3.68B -159B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/04/26 | 108.85 $ | +1.61% | 581,475 |
| 21/04/26 | 107.13 $ | -1.03% | 787,206 |
| 20/04/26 | 108.24 $ | +0.59% | 402,906 |
| 17/04/26 | 107.61 $ | +3.61% | 772,833 |
| 16/04/26 | 103.86 $ | -0.85% | 591,160 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NUVL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition